Novozymes A/s

Novozymes, Inc.

Solvay Pharmaceuticals, Gmbh

Peter Colin Gregory

Allan Svendsen

Signe Eskildsen Larsen

Michael Lamsa

Lars Lehmann Hylling Christensen

Michael Skjoet

Nina Lundin

Debbie Sue Yaver

Lars Beier

Jochen Antel

Harald Waldeck

Dan Pettersson

Michael Wurl

Tanja Maria Rosenkilde Kjaer

Thomas Lenhard

Deborah Yaver

Sabine Eyting

Maike Wolff

Lars Lehmann Christensen

Nina Vibeke Fabricius Lundin

The pharmaceutical use of lipases related to the() lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of

Lipase variants for pharmaceutical use

The pharmaceutical use of lipases related to the() lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of

The invention relates to novel variants of a protease derived fromsp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.

Protease variants for pharmaceutical use

Substituted &#x3b2;-lactones (oxetanones) corresponding to the formula I, wherein R, Rand n have the meanings given in the specification, and pharmaceutical compositions which contain these compounds and have a pancreatic lipase-inhibiting action, as well as a process for the preparation of the compounds of Formula I and intermediate products of this process.

Alkyl carbamate-substituted &#x3b2;-lactones, process for their preparation, and pharmaceutical compositions containing them

Growing community of inventors

Hannover, Germany

Peter Colin Gregory